Literature DB >> 23692156

Annual immunisation coverage report, 2010.

Brynley Hull1, Aditi Dey, Rob Menzies, Peter McIntyre.   

Abstract

This, the fourth annual immunisation coverage report, documents trends during 2010 for a range of standard measures derived from Australian Childhood Immunisation Register (ACIR) data. These include coverage at standard age milestones and for individual vaccines included on the National Immunisation Program (NIP). For the first time, coverage from other sources for adolescents and the elderly are included. The proportion of children 'fully vaccinated' at 12, 24 and 60 months of age was 91.6%, 92.1% and 89.1% respectively. For vaccines available on the NIP but not currently assessed for 'fully immunised' status or for eligibility for incentive payments (rotavirus and pneumococcal at 12 months and meningococcal C and varicella at 24 months) coverage varied. Although pneumococcal vaccine had similar coverage at 12 months to other vaccines, coverage was lower for rotavirus at 12 months (84.7%) and varicella at 24 months (83.0%). Overall coverage at 24 months of age exceeded that at 12 months of age nationally and for most jurisdictions, but as receipt of varicella vaccine at 18 months is excluded from calculations, this represents delayed immunisation, with some contribution from immunisation incentives. The 'fully immunised' coverage estimates for immunisations due by 60 months increased substantially in 2009, reaching almost 90% in 2010, probably related to completed immunisation by 60 months of age being introduced in 2009 as a requirement for GP incentive payments. As previously documented, vaccines recommended for Indigenous children only (hepatitis A and pneumococcal polysaccharide vaccine) had suboptimal coverage at around 57%. Delayed receipt of vaccines by Indigenous children at the 60-month milestone age improved from 56% to 62% but the disparity in on-time vaccination between Indigenous and non-Indigenous children at earlier age milestones did not improve. Coverage data for human papillomavirus (HPV)from the national HPV register are consistent with high coverage in the school-based program (73%) but were lower for the catch-up program for women outside school (30-38%). Coverage estimates for vaccines on the NIP from 65 years of age were comparable with other developed countries.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23692156

Source DB:  PubMed          Journal:  Commun Dis Intell Q Rep        ISSN: 1447-4514


  5 in total

1.  An assessment of measles vaccine effectiveness, Australia, 2006-2012.

Authors:  Alexis Pillsbury; Helen Quinn
Journal:  Western Pac Surveill Response J       Date:  2015-07-09

2.  No long-term evidence of hyporesponsiveness after use of pneumococcal conjugate vaccine in children previously immunized with pneumococcal polysaccharide vaccine.

Authors:  Paul V Licciardi; Zheng Quan Toh; Elizabeth A Clutterbuck; Anne Balloch; Rachel A Marimla; Leena Tikkanen; Karen E Lamb; Kathryn J Bright; Uraia Rabuatoka; Lisi Tikoduadua; Laura K Boelsen; Eileen M Dunne; Catherine Satzke; Yin Bun Cheung; Andrew J Pollard; Fiona M Russell; Edward K Mulholland
Journal:  J Allergy Clin Immunol       Date:  2016-01-26       Impact factor: 10.793

3.  Evaluating the implementation of the 13-valent pneumococcal vaccine supplementary dose program in Australian primary health care settings.

Authors:  Kirsten F Ward; Marianne Trent; Brynley P Hull; Helen E Quinn; Aditi Dey; Robert I Menzies
Journal:  BMC Health Serv Res       Date:  2015-03-18       Impact factor: 2.655

4.  Characterization of a G1P[8] rotavirus causing an outbreak of gastroenteritis in the Northern Territory, Australia, in the vaccine era.

Authors:  Celeste M Donato; Daniel Cowley; Thomas L Snelling; Asmik Akopov; Ewen F Kirkness; Carl D Kirkwood
Journal:  Emerg Microbes Infect       Date:  2014-07-02       Impact factor: 7.163

5.  Quality of social and emotional wellbeing services for families of young Indigenous children attending primary care centers; a cross sectional analysis.

Authors:  Karen M Edmond; Kimberley McAuley; Daniel McAullay; Veronica Matthews; Natalie Strobel; Rhonda Marriott; Ross Bailie
Journal:  BMC Health Serv Res       Date:  2018-02-09       Impact factor: 2.655

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.